A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group

Leukemia. 2016 Oct;30(10):2077-2080. doi: 10.1038/leu.2016.119. Epub 2016 May 2.

Authors

L Eidenschink Brodersen¹, T A Alonzo^{2

3}, A J Menssen¹, R B Gerbing², L Pardo¹, A P Voigt¹, S B Kahwash⁴, B Hirsch⁵, S Raimondi⁶, A S Gamis^{2

7}, S Meshinchi^{2

8}, M R Loken¹

Affiliations

¹ HematoLogics, Inc, Seattle, WA, USA.
² Children's Oncology Group, Monrovia, CA, USA.
³ University of Southern California, Los Angeles, CA, USA.
⁴ Nationwide Children's Hospital, Columbus, OH, USA.
⁵ University of Minnesota Medical Center, Minneapolis, MN, USA.
⁶ St. Jude's Children's Research Hospital, Memphis, TN, USA.
⁷ Children's Mercy Hospitals & Clinics, Kansas City, MO, USA.
⁸ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adolescent
Child
Child, Preschool
Humans
Immunophenotyping*
Infant
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / immunology*
Risk Factors

Associated data

ClinicalTrials.gov/NCT00372593

Grants and funding